MedTrace Logo

Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination

NCT05009134 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-03-17

No results posted yet for this study

Summary

The study is designed to assess whether allergic rhinitis and allergen immunotherapy affect the humoral response to SARS-CoV-2 Vaccination in adults. This is a prospective study enrolling a total of approximately 120 subjects, 18-55 years old.

Conditions

  • Allergic Rhinitis
  • Allergen Immunotherapy
  • SARS-CoV-2

Interventions

BIOLOGICAL

There is no intervention in this study.

There is no intervention in this study.

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Zheng Liu, Doctor · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-04
Primary Completion
2022-03-20
Completion
2022-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05009134 on ClinicalTrials.gov